Onkolojik Tedaviye Bağlı Tromboembolik Hastalıklarda Tanı ve Tedavi Yaklaşımları

DiNisio M, Ferrante N, Feragalli B, et al. Arterialthrombosis in ambulatorycancerpatientstreatedwithchemotherapy. ThrombRes.2011;127:382 –383

Lecumberri R, Marques M, Panizo E, et al. High incidence of venousthromboembolismdespiteelectronicalertsforthromboprophylaxis in hospitalisedcancerpatients. ThrombHaemost. 2013;110:184-190.

Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associatedvenousthrombosis. Blood. 2013;122:1712-23.

Blom JW. Malignancies, prothromboticmutations, andthe risk of venousthrombosis. JAMA.2005;293:715.

Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, andtrendsforvenousthromboembolismamonghospitalizedcancerpatients. Cancer. 2007;110:233-46.

Wells PS, Anderson DR, Rodger M, et al. Derivation of a simpleclinical model tocategorizepatientsprobability of pulmonaryembolism: increasingthemodelsutilitywiththeSimpliRED D-dimer. ThrombHaemost. 2000;83:416-420

Le Gal G, Righini M, Roy PM, et al. Prediction of pulmonaryembolism in theemergencydepartment: therevisedGenevascore. AnnInternMed.2006;144:165-171.

Klok FA, Mos IC, Nijkeuter M, et al. Simplification of therevisedGenevascoreforassessingclinicalprobability of pulmonaryembolism. ArchInternMed.2008;168:2131-2136.

Barco S, Ende-Verhaar YM, Becattini C, et al. Differentialimpact of syncope on theprognosis of patientswithacutepulmonaryembolism: a systematicreviewand meta-analysis. EurHeart J. 2018;39:4186-4195.

Shopp JD, Stewart LK, Emmett TW, et al. Findingsfrom 12-lead electrocardiographythatpredictcirculatoryshockfrompulmonaryembolism: systematicreviewand meta-analysis. AcadEmergMed.2015;22:1127-1137.

Stein PD, Hull RD, Patel KC, et al. D-dimerfortheexclusion of acutevenousthrombosisandpulmonaryembolism. AnnInternMed. 2004; 140: 589-602.

DiNisio M, Sohne M, Kamphuisen PW, et al. D-Dimer test in cancerpatientswithsuspectedacutepulmonaryembolism. J ThrombHaemost.2005; 3: 1239-42.

Konstantinides SV, Meyer G, Becattini C, et al; ESC ScientificDocumentGroup. 2019 ESC Guidelinesforthediagnosisandmanagement of acutepulmonaryembolismdeveloped in collaborationwiththeEuropeanRespiratorySociety (ERS). EurHeart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405.

van der Hulle T, Cheung WY, Kooij S, et al, YearsStudyGroup. Simplifieddiagnosticmanagement of suspectedpulmonaryembolism (the YEARS study): a prospective, multicentre, cohortstudy. Lancet.2017;390:289-297.

Righini M, Goehring C, Bounameaux H, et al. Effects of age on theperformance of commondiagnostictestsforpulmonaryembolism. Am J Med. 2000;109:357-361.

Righini M, Van Es J, Den Exter PL, et al. Age-adjustedDdimercut-offlevelstoruleoutpulmonaryembolism: the ADJUST-PE study. JAMA.2014;311:1117-1124.

Becattini C, Vedovati MC, Agnelli G. Prognosticvalue of troponins in acutepulmonaryembolism: a meta-analysis. Circulation. 2007;116:427-433.

Lankeit M, Friesen D, Aschoff J, et al. Highlysensitivetroponin T assay in normotensivepatientswithacutepulmonaryembolism. EurHeart J. 2010;31:18361-844.

Klok FA, Mos IC, Huisman MV. Brain-typenatriureticpeptidelevels in theprediction of adverseoutcome in patientswithpulmonaryembolism: a systematicreviewand meta-analysis. Am J RespirCritCareMed.2008;178:425-430.

Agterof MJ, Schutgens RE, Snijder RJ, et al. Out of hospitaltreatment of acutepulmonaryembolism in patientswith a low NT-proBNPlevel. J ThrombHaemost. 2010;8:1235-1241.

Vanni S, Nazerian P, Bova C, et al. Comparison of clinicalscoresforidentification of patientswithpulmonaryembolism at intermediate-high risk of adverseclinicaloutcome: theprognostic role of plasmalactate. InternEmergMed. 2017;12:657-665.

Kostrubiec M, Plywaczewska M, Jime´nez D, et al. Theprognosticvalue of renalfunction in acutepulmonaryembolismamulti-centrecohortstudy. ThrombHaemost. 2019;119:140-148

Zhou XY, Chen HL, Ni SS. Hyponatremiaandshort-termprognosis of patientswithacutepulmonaryembolism: a meta-analysis. Int J Cardiol.2017;227:251-256.

Kostrubiec M, Labyk A, Pedowska-Wloszek J, et al. Neutrophilgelatinase-associatedlipocalin, cystatin C andeGFRindicateacutekidneyinjuryandpredictprognosis of patientswithacutepulmonaryembolism. Heart. 2012;98:1221-1228

Vuilleumier N, Simona A, Mean M, et al. Comparison of cardiacandnon-cardiacbiomarkersfor risk stratification in elderlypatientswithnon-massivepulmonaryembolism. PLoSOne. 2016;11:e0155973.

Rodger MA, Carrier M, Jones GN, et al. Diagnosticvalue of arterialbloodgasmeasurement in suspectedpulmonaryembolism. Am J RespirCritCareMed. 2000;162:2105-2108.

Stein PD, Fowler SE, Goodman LR, et al; PIOPED II Investigators. Multidetectorcomputedtomographyforacutepulmonaryembolism. N Engl J Med. 2006;354:2317-2327.

Glaser JE, Chamarthy M, Haramati LB, et al. Successfulandsafeimplementation of a trinaryinterpretationandreportingstrategyfor V/Q lungscintigraphy. J NuclMed. 2011;52:1508-1512.

Stein PD, Athanasoulis C, Alavi A, et al. Complicationsandvalidity of pulmonaryangiography in acutepulmonaryembolism. Circulation. 1992;85:462-468.

Kurnicka K, Lichodziejewska B, Goliszek S, et al. Echocardiographicpattern of acutepulmonaryembolism: analysis of 511 consecutivepatients. J AmSocEchocardiogr.2016;29:907-913.

Roy PM, Colombet I, Durieux P, et al. Systematicreviewand meta-analysis of strategiesforthediagnosis of suspectedpulmonaryembolism. BMJ.2005;331:259.

Kurzyna M, Torbicki A, Pruszczyk P, et al. Disturbedrightventricularejectionpattern as a newDopplerechocardiographicsign of acutepulmonaryembolism. Am J Cardiol. 2002;90:507-511.

Casazza F, Becattini C, Guglielmelli E, et al. Prognosticsignificance of free-floatingrightheartthromboemboli in acutepulmonaryembolism: resultsfromtheItalianPulmonaryEmbolismRegistry. ThrombHaemost.2014;111:5357.

Casazza F, Bongarzoni A, Centonze F, et al. Prevalenceandprognosticsignificance of right-sidedcardiac mobile thrombi in acutemassivepulmonaryembolism. Am J Cardiol.1997;79:1433-1435.

Perrier A, Bounameaux H. Ultrasonography of legveins in patientssuspected of havingpulmonaryembolism. AnnInternMed. 1998;128:243-253.

Prandoni P, Siragusa S, Girolami B, et al; BELZONI InvestigatorsGroup. Theincidence of heparin-inducedthrombocytopenia in medicalpatientstreatedwithlow-molecular-weightheparin: a prospectivecohortstudy. Blood.2005;106:3049-3054

Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factorXainhibitorwithlowmolecularweightheparin in patientswithcancerwithvenousthromboembolism: results of a randomized Trial (SELECT-D). J ClinOncol. 2018;36:2017-23.

Raskob GE, van Es N, Verhamme P. Edoxabanforthetreatment of cancer-associatedvenousthromboembolism. N Engl J Med.2018;378:615-24.

Hakoum MB, Kahale LA, Tsolakian IG, et al. Anticoagulationfortheinitialtreatment of venousthromboembolism in peoplewithcancer. Cochrane Database SystRev. 2018;1:CD006649.

Posch F, Konigsbrugge O, Zielinski C, et al. Treatment of venousthromboembolism in patientswithcancer: a network meta-analysiscomparingefficacyandsafety of anticoagulants. ThrombRes 2015;136:582-589.

Vedovati MC, Germini F, Agnelli G. Direct oral anticoagulants in patientswith VTE andcancer: a systematicreviewand meta-analysis. Chest. 2015;147:475-83.

Raskob GE, van Es N, Verhamme P, et al; Hokusai VTE CancerInvestigators. Edoxabanforthetreatment of cancer-associatedvenousthromboembolism. N Engl J Med. 2018;378:615-624.

Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, et al.Tinzaparin in cancerassociatedthrombosisbeyond 6months: TiCATstudy. ThrombRes. 2017;157:90-96.

Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venousthromboembolism in cancerpatientswithdalteparinforupto 12 months: the DALTECAN study. J ThrombHaemost. 2015;13: 1028-1035.

Napolitano M, Saccullo G, Malato A, et al. Optimal duration of lowmolecularweightheparinforthetreatment of cancer-relateddeepveinthrombosis: theCancer-DACUS Study. J ClinOncol. 2014;32:3607-3612.

Rafii H, Frère C, Benzidia I, et al. Management of cancer-relatedthrombosis in theera of direct oral anticoagulants: A comprehensivereview of the 2019 ITAC-CME clinicalpracticeguidelines. On behalf of theGroupeFrancophoneThrombose et Cancer (GFTC). J MedVasc. 2020 Feb;45(1):28-40.doi: 10.1016/j.jdmv.2019.12.004.

IliescuC. A,Girnes CL, Herrman J,et al. SCAI ExpertConsensus Statement: evaluation, management, andspecialconsiderations of cardio-oncologypatients in thecardiaccatheterizationlaboratory (endorsedbytheCardiologicalSociety of India, andSociedadLatinoAmericana de CardiologiaIntervencionista). CatheterCardiovascInterv, 87, E202–E223 (2016).

NeumannFJ,Sousa-Uva M, Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardialrevascularization. EurHeart J,40, 87-165 (2019).

UrbanP, Meredith IT, Abizaid A, et al. Polymer-freedrug-coatedcoronarystents in patients at highbleeding risk. NEnglJMed, 373, 2038-2047 (2015)

TouyzRM, HerrmannSMS, HerrmannJ. Vasculartoxicitieswith VEGF inhibitortherapies-focus on hypertensionandarterialthromboticevents. JAmSocHypertens, 12, 409-425 (2018)